Halozyme Therapeutics, Inc.
HALO
$50.23
-$16.35-24.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 264.86M | 298.01M | 290.08M | 231.35M | 195.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 264.86M | 298.01M | 290.08M | 231.35M | 195.88M |
| Cost of Revenue | 51.63M | 62.50M | 67.88M | 60.65M | 31.67M |
| Gross Profit | 213.23M | 235.51M | 222.20M | 170.71M | 164.21M |
| SG&A Expenses | 42.36M | 42.25M | 41.24M | 35.71M | 35.13M |
| Depreciation & Amortization | 17.76M | 17.76M | 17.76M | 17.76M | 17.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.33M | 122.51M | 126.89M | 114.12M | 100.34M |
| Operating Income | 141.54M | 175.50M | 163.20M | 117.24M | 95.54M |
| Income Before Tax | 143.83M | 178.21M | 165.15M | 117.74M | 96.03M |
| Income Tax Expenses | 25.73M | 41.20M | 28.14M | 24.50M | 19.21M |
| Earnings from Continuing Operations | 118.10M | 137.01M | 137.01M | 93.25M | 76.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 118.10M | 137.01M | 137.01M | 93.25M | 76.82M |
| EBIT | 141.54M | 175.50M | 163.20M | 117.24M | 95.54M |
| EBITDA | 160.48M | 194.52M | 182.16M | 136.07M | 114.35M |
| EPS Basic | 0.96 | 1.08 | 1.08 | 0.73 | 0.61 |
| Normalized Basic EPS | 0.72 | 0.87 | 0.81 | 0.58 | 0.46 |
| EPS Diluted | 0.93 | 1.06 | 1.05 | 0.72 | 0.60 |
| Normalized Diluted EPS | 0.70 | 0.85 | 0.79 | 0.57 | 0.45 |
| Average Basic Shares Outstanding | 123.22M | 126.41M | 126.85M | 127.12M | 126.94M |
| Average Diluted Shares Outstanding | 126.64M | 128.98M | 130.13M | 129.22M | 128.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |